ADVFN Logo
Registration Strip Icon for alerts Register for real-time alerts, custom portfolio, and market movers

XERS Xeris Biopharma Holdings Inc

1.85
-0.06 (-3.14%)
Apr 15 2024 - Closed
Delayed by 15 minutes

Period:

Draw Mode:

Volume 1,773,740
Bid Price 1.85
Ask Price 1.89
News -
Day High 1.96

Low
1.46

52 Week Range

High
3.26

Day Low 1.83
Company Name Stock Ticker Symbol Market Type
Xeris Biopharma Holdings Inc XERS NASDAQ Common Stock
  Price Change Change Percent Stock Price Last Traded
-0.06 -3.14% 1.85 20:00:00
Open Price Low Price High Price Close Price Prev Close
1.90 1.83 1.96 1.85 1.91
Trades Volume VWAP Dollar Volume Avg Volume 52 Week Range
6,167 1,773,740 $ 1.88 $ 3,336,350 - 1.46 - 3.26
Last Trade Time Type Quantity Stock Price Currency
19:36:55 5 $ 1.86 USD

Xeris Biopharma Holdings Inc Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
261.24M 140.45M - 163.91M -62.26M -0.44 -
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- - - -

more financials information »

Xeris Biopharma News

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....


No posts yet, be the first! No XERS Message Board. Create One! See More Posts on XERS Message Board See More Message Board Posts

Historical XERS Price Data

Period Open High Low VWAP Avg. Daily Vol Change %
1 Week2.052.0651.831.981,391,487-0.20-9.76%
1 Month2.252.27991.832.081,427,899-0.40-17.78%
3 Months2.413.261.832.571,927,215-0.56-23.24%
6 Months1.743.261.462.361,891,4310.116.32%
1 Year2.183.261.462.391,486,184-0.33-15.14%
3 Years4.074.980.97012.491,837,615-2.22-54.55%
5 Years9.7312.980.97013.231,637,715-7.88-80.99%

Xeris Biopharma Description

Xeris Biopharma Holdings, Inc., a biopharmaceutical company, engages in developing and commercializing therapies in Illinois. The company markets Gvoke, a ready-to-use liquid-stable glucagon for the treatment of severe hypoglycemia; and Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor proved for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome. It also has a pipeline of development programs to extend the marketed products into new indications and uses and bring new products using its proprietary formulation technology platforms, XeriSol and XeriJect. The company was incorporated in 2005 and is headquartered in Chicago, Illinois.

Your Recent History

Delayed Upgrade Clock